Lees in het Nederlands

Market access in pharma

The core objective of pharmaceutical market access teams is to ensure that patients in need have timely and sustained access to (new) treatments. However, today’s market access environment is more challenging than ever before, putting patient access to life saving treatments in jeopardy.


The market access challenge continues

Continuous technological advances and demographic trends will put additional pressure on healthcare budgets, forcing payers to take austerity measures and scrutinize budget allocation decisions. Payers want to see increasingly compelling and real-life evidence of a drug’s superior value combined with pricing and payment schemes that will minimize risk for their healthcare system.


Excellent market access teams are ready to face these challenges by:

  • Developing market access strategies focussed on demonstrating real value and minimizing risk for the organization and external stakeholders;
  • Organizing in cross-functional teams that are involved in early development (latest from phase II onwards);
  • Collaborating with national and local payers to ensure timely and honest feedback on market access strategies, dossiers and solutions.


How we help you navigate this challenging environment

Our extensive national and international experience in strategy and organizational change in the pharmaceutical industry, combined with access to internal and external subject matter expertise, positions us as your go-to-partner for your market access challenges. Our solutions in the market access area are structured across four capabilities:

  • Strategy: develop compelling pricing, reimbursement and market access strategies.
  • Demonstrate value: support business case development demonstrating superior value.
  • Organization: organize for market access success.
  • Payer network: obtain timely and honest feedback via our payer network.


Market Access proposition


Figure 1: Four Market Access Capabilities



read more about the 4 capabilities in market access


Market access expertise with strong academic basis

We ensure our market access advisory projects are strongly linked to latest academic insights through our expert in health economics Prof. dr. Lieven Annemans. Prof. dr. Lieven Annemans is professor of Health-Economics at Ghent University. He is one of Europe’s leading experts in health economics and HTA. Annemans is a sought-after advisor and educator to health policy makers and pharma and device companies. He is highly respected for his vast international and cross-therapeutic experience and is the academic backbone of our Market Access practice.


Obtain timely and honest feedback from our payer network

Are you seeking external validation of your market access, pricing or reimbursement strategy? We can mobilize our European payer network via interviews, surveys or advisory boards to help you get external validation early and efficiently. Explore the possibilities.


Our latest thinking

In this WHITE PAPER we describing a holistic approach to Innovative Agreements and Partnerships, and how to drive true Value Demonstration. Read our new white paper on the necessary steps to take and how Innovative Agreements and Partnerships will ultimately affect pharma and healthcare business models. Read the full version and download it now!

Risks related to the introduction of new medicines: to share or not to share? Lieven Annemans explains the different types of risk sharing agreements and how risk sharing agreements can play an important role in achieving optimal patient access to new medicines. View here.

In this whitepaper, we provide a framework to help pharma and payers start a new dialogue and explore where they might find common ground. Download our whitepaper.

Most pharmaceutical companies are organized in a matrix structure. We often see that this potentially highly effective structure is not so effective in practice. Read why.

The political and social backlash against high costs for innovative therapies is growing. A creative solution is needed to reduce costs and stimulate innovation at the same time. Read more.

more information?

See examples of projects we have recently completed for global pharmaceutical companies. Do you want more information or want to get started? Please contact Bas Amesz, Christel Jansen or Karst-Jan de Jong.


Manager cjansen@vintura.com

I focus on business consultancy, making use of my experience in project management and strategy development. My strength lies where strategy and operations meet.